RCS - Agronomics Limited - All G secures FDA "no questions" letter

AgronomicsAnnouncement

Yesterday 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260401:nRSA1057Za&default-theme=true

RNS Number : 1057Z  Agronomics Limited  01 April 2026

 

Agronomics Limited

("Agronomics" or the "Company")

All G secures FDA "no questions" letter for precision fermented lactoferrin

 

DOUGLAS, ISLE OF MAN / 1 April 2026 - Agronomics (LSE: ANIC), a London-listed
company focused on investment opportunities in the clean food sector,
announces that its portfolio company, All G Co Holdings Pty Limited ("All G"),
has completed the U.S. Food and Drug Administration's ("FDA") Generally
Recognized as Safe ("GRAS") notification process for its precision fermented
bovine lactoferrin.

 

All G has received a "no questions" letter from the FDA, confirming that the
agency has no questions at this time regarding All G's conclusion that its
recombinant lactoferrin is safe for use in food. This outcome enables the
ingredient's commercialisation in the United States, a significant market for
functional ingredients and dietary supplements.

 

All G is an Australian biotechnology company developing next-generation milk
proteins using precision fermentation. Its lactoferrin product, marketed as
LFX™, is intended for use in functional food and beverage applications,
dietary supplements and early life nutrition. The company states that the
ingredient is produced through a controlled fermentation process and purified
to defined specifications, with analytical testing indicating purity levels in
excess of 99.5%.

 

Agronomics considers this regulatory clearance an important step for All G,
supporting near-term commercial activity in the United States and providing a
broad reference point for precision fermented functional proteins. The
development is consistent with Agronomics' strategy of investing in scalable,
high-value ingredients with defined commercial pathways.

 

Jim Mellon, Executive Chair of Agronomics, said: "FDA clearance for All G's
precision fermented lactoferrin is an important milestone for the company and
for the broader precision fermentation sector. Regulatory validation of this
kind reduces uncertainty around commercial deployment and supports the
transition from technical development to revenue generation. All G operates in
a category characterised by strong demand, constrained traditional supply and
attractive pricing dynamics. We believe this outcome positions the company to
establish itself as a supplier of high-value functional proteins to global
nutrition markets."

 

Lactoferrin has an established history of use in the United States, including
in infant formula, dietary supplements and functional foods. All G has
indicated that the GRAS determination is expected to support its broader
regulatory strategy, including future applications in early life nutrition and
expansion into additional jurisdictions.

 

Agronomics first invested in All G in August 2022 and has subscribed a total
of £8.9 million to date, which, subject to audit, is currently carried at
approximately £7.4 million. This position represents around 5% of Agronomics'
most recently reported Net Asset Value of £139.9 million as at 31 December
2025. Agronomics invested an additional AU$ 3 million in All G in January 2026
through a convertible loan. The Company will provide further updates as All G
progresses toward commercial launch.

About All G

All G is an Australian biotechnology company developing next-generation human
and bovine milk proteins using precision fermentation technology. The company
is advancing a portfolio of recombinant proteins, including lactoferrin, to
enable nutrition formulations with improved functionality, consistency and
scalability.

About Agronomics

Agronomics is a leading London-listed company focused on investment
opportunities in the clean food sector. The Company has built a diversified
portfolio spanning cellular agriculture, precision fermentation and enabling
biomanufacturing technologies.

A full list of Agronomics' portfolio companies is available
at www.agronomics.im (http://www.agronomics.im/) .

For further information, please contact:

 Agronomics Limited                               Beaumont Cornish Limited  Canaccord Genuity Limited  Cavendish Capital Markets Limited   33Seconds Limited

 The Company                                      Nomad                     Joint Broker               Joint Broker                        Public Relations

 Jim Mellon                                       Roland Cornish            Andrew Potts               Giles Balleny                       Jack Ferris

Amber Carr
 Denham Eke                                       James Biddle              Harry Pardoe               Michael Johnson

 +44 (0) 1624 639396                              +44 (0) 207 628 3396      +44 (0) 207 523 8000       +44 (0) 207 397 8900                +44 (0) 207 469 0936

 info@agronomics.im (mailto:info@agronomics.im)                                                                                            agronomics@33seconds.co (mailto:agronomics@33seconds.co)

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media-only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUQCCUPQGGG



            Copyright 2019 Regulatory News Service, all rights reserved